Association of Pro12Ala (rs1801282) PPARG with PPARG mRNA levels in visceral abdominal tissue in females

Obesity is considered to be a rapidly growing health problem worldwide. The factors that regulate body fat content and distribution are not fully understood. Our study aimed to investigate whether the Pro12Ala (rs1801282) polymorphism of the PPARG gene may influence on PPARG expression in visceral adipose tissue in fertile women in Russia. The study included 27 women without type 2 diabetes mellitus and cardiovascular dysfunction (mean age 43.00 (30.00-49.00), BMI 28.73 (18.13-56.18) kg/m²). Genotyping of the Pro12Ala PPARG polymorphisms were determined by PCR-RFLP assay. PPARG expression were estimated by RT-PCR with TaqMan probes. Our results demonstrated that mRNA PPARG level was significantly lower in subjects with the 12Ala allele (AlaAla+AlaPro) than in ProPro genotype carriers (p = 0,029). In conclusion, we demonstrate that the Pro12Ala PPARG polymorphism may influence to the observed variability in PPARG expression in visceral adipose tissue and thereby contribute to the pathogenesis of abdominal obesity in fertile women.

жировая ткань, экспрессия генов, PPARG, полиморфные варианты, adipose tissue, gene expression, PPARG, polymorphic variants

1. Mendis S. Global atlas on cardiovascular disease prevention and control 2011. World Health Organization. 2013. URL: http://www.who.int/cardiovascular_diseases/

2. Halberg N, Wernstedt I, Scherer PE. The Adipocyte as an Endocrine Cell. Endocrinol. Metab. Clin. North Am. 2008; 37(3):753-768. DOI: 10.1016/j.ecl.2008.07.002.

3. Wajchenberg BL, Giannella-Neto D, da Silva ME, et al. Depotspecific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm. Metab. Res. 2002;34:616-621. DOI: 10.1055/s-2002-38256.

4. Grygiel-Gorniak. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review. Nutr J. 2014;13:17. DOI: 10.1186/1475-2891-13-17.

5. Jeninga, EH, Gurnell, M, Kalkhoven E. Functional implications of genetic variation in human PPARg. Trends Endocrinol. Metab. 2009;20:380-387. DOI: 10.1016/j.tem.2009.04.005

6. Gema Medina-Gomez, Sarah L. Gray, Laxman Yetukuri, et al. PPAR gamma 2 Prevents Lipotoxicity by Controlling Adipose Tissue Expandability and Peripheral Lipid Metabolism. PLoS Genet. 2007;3(4):634-647. DOI: 10.1371/journal.pgen.0030064.

7. Chistiakov DA. The PPARg Pro12Ala variant is associated with insulin sensitivity in Russian normoglycaemic and type 2 diabetic subjects. 2010;(7):156-62. DOI: 10.1177/1479164109347689.

8. Gonzalez Sanchez JL, Serrano Rios M., Fernandez Perez C., et al. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur. J. Endocrinol. 2002;147:495-501. URL: http://www.eje.org.

9. Costa V, Gallo MA, Letizia F, et al. PPARG: Gene Expression Regulation and Next-Generation Sequencing for Unsolved Issues. PPAR Research. 2010;2010:17. DOI:10.1155/2010/409168.

10. Doney A, Fischer B, Frew D, et al. Haplotype analysis of the PPARg Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genetics. 2002;3:21. DOI:10.1186/1471-2156-3-21.

11. Capaccio D, Ciccodicola A, Sabatino L, et al. A novel germline mutation in peroxisome proliferator-activated receptor gamma gene associated with large intestine polyp formation and dyslipidemia. Biochim Biophys Acta. 2010; 1802(6):572-81. DOI: 10.1016/j.bbadis.2010.01.012

12. Agostini M, Schoenmakers E, Mitchell C, et al. Non-DNA binding, dominant-negative, human PPARg mutations cause lipodystrophic insulin resistance. Cell Metabolism. 2006;4(4):303-311. doi:10.1016/j.cmet.2006.09.003.

13. http://docs.appliedbiosystems.com/pebiodocs/04303859.pdf

14. Berhouma R, Kouidhi S, Ammar M, et al. Correlation of Peroxisome Proliferator-Activated Receptor (PPAR-g) mRNA Expression with Pro12Ala Polymorphism in Obesity. Biochem Genet. 2013;(51):256-263. DOI: 10.1007/s10528-012-9560-y.

15. Усенко ТС, Мирошникова ВВ, Баженова ЕА и др. Экспрессия генов ITLN1, PPARg и TNFa в интраабдоминальной жировой ткани. Цитология. 2016 (в печати)

16. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARc2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20:284-287. DOI: 10.1038/3099.

17. Rosen ED, Hsu C-H, Wang X, et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 2002;16(1):22-26. DOI: 10.1101/gad.948702.

18. Lee J-E, Ge K. Transcriptional and epigenetic regulation of PPARg expression during adipogenesis. Cell Biosci. 2014;4(1):29-39. DOI: 10.1186/2045-3701-4-29.

19. Zarebska A, Jastrzebski Z, Cieszczyk P, et al. The Pro12Ala Polymorphism of the Peroxisome Proliferator-Activated Receptor Gamma Gene Modifies the Association of Physical Activity and Body Mass Changes in Polish Women. PPAR Res. 2014;7. DOI: 10.1155/2014/373782.

20. Li Y, Zhu J, Ding JQ. Association of the PPARg2 Pro12Ala polymorphism with increased risk of cardiovascular diseases. Genet. Mol. Res. 2015;14(4):18662-18674. DOI: 10.4238/2015.